AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1734903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air
Number of subjects: 42
Study 1734903 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Number of subjects: 42
Study 1734903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligno-paraffin
Number of subjects: 42
Study 6426846 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine administration (20 and 25 mg/kg body weight)
Number of subjects: 4
Study 31222496 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced POSE 18-plication
Number of subjects: 15
Study 31222496 — intervention group
Group type: COMPARATOR
Intervention: Standard POSE method
Number of subjects: 15
Study 29805981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg
Number of subjects: 72
Study 29805981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27823695 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic per-postconditioning (RIperpostC)
Number of subjects: 93
Study 27823695 — intervention group
Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 93
Study 25015176 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Number of subjects: 100
Study 25015176 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg
Number of subjects: 100
Study 25015176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22608375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and counseling for smoking cessation
Number of subjects: 1346
Study 22608375 — intervention group
Group type: COMPARATOR
Intervention: Matched community-dwelling smokers
Number of subjects: 1346
Study 22608375 — intervention group
Group type: COMPARATOR
Intervention: Trial participants who continued smoking
Number of subjects: 1346
Study 20813531 — intervention group
Group type: EXPERIMENTAL
Intervention: New upper extremity sparing non-weight bearing orthosis
Number of subjects: 10
Study 17209669 — intervention group
Group type: COMPARATOR
Intervention: Limaprost 30 microg/day
Number of subjects: 282
Study 17209669 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost 15 microg/day
Number of subjects: 282
Study 15309457 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla extract (PE) containing 200 mg rosmarinic acid (RA)
Number of subjects: 6
Study 15309457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11886692 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 148
Study 11886692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 148
Study 11886692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 11886692 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 148
Study 9821422 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (initiation at 4 days of age)
Number of subjects: 135
Study 9821422 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding (initiation at 15 days of age)
Number of subjects: 135
Study 9821422 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk feeding
Number of subjects: 135
Study 9821422 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 135
Study 9821422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase activity
Number of subjects: 135
Study 7653809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus injections of propofol (10 mg) after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63
Study 7653809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional syringe infusion pump (25-100 micrograms.kg-1.min-1) after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63
Study 7653809 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) device with initial target concentration of 2 micrograms/mL adjusted between 1 and 4 micrograms/mL after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63
Study 2173391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol, 10 mg plus placebo q.i.d.
Number of subjects: 19
Study 2173391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine, 10 mg plus placebo q.i.d.
Number of subjects: 19
Study 2173391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol plus prochlorperazine, each 10 mg q.i.d.
Number of subjects: 19
Study 76794 — intervention group
Group type: EXPERIMENTAL
Intervention: Home management group
Number of subjects: 349
Study 76794 — intervention group
Group type: COMPARATOR
Intervention: Hospital management group
Number of subjects: 349
Study 29886146 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCT group
Number of subjects: 255
Study 29886146 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 29886146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study 28732773 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (tenofovir monotherapy or combination of tenofovir and emtricitabine)
Number of subjects: 1470
Study 28732773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1470
Study 24875466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) starting on the first postoperative day
Number of subjects: 109
Study 24875466 — intervention group
Group type: COMPARATOR
Intervention: Late oral feeding (LOF) remaining nil by mouth until the return of bowel sounds
Number of subjects: 109
Study 23557249 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care management intervention
Number of subjects: 5074
Study 23557249 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service system without care management services
Number of subjects: 5074
Study 21570517 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 7761
Study 21570517 — intervention group
Group type: COMPARATOR
Intervention: Standard care without LVH
Number of subjects: 7761
Study 21570517 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of quantitative ST depression (STD) among LVH patients
Number of subjects: 7761
Study 21570517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic-determined LVH
Number of subjects: 7761
Study 21570517 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression (STD)
Number of subjects: 7761
Study 19261545 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Patient Programme (EPP)
Number of subjects: 192
Study 19261545 — intervention group
Group type: COMPARATOR
Intervention: Control Group (wait-list for EPP)
Number of subjects: 192
Study 17112855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 2 x 600 mg/d for 3 months (GI)
Number of subjects: 22
Study 17112855 — intervention group
Group type: COMPARATOR
Intervention: Control group (GII) not receiving PTX
Number of subjects: 22
Study 15701267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α-hydroxy-24-ethyl-cholecalciferol (vitamin D5)
Number of subjects: 0
Study 15701267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11376256 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hour two dose of 225 mL dilute contrast material
Number of subjects: 56
Study 11376256 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hour five dose of 225 mL dilute contrast material
Number of subjects: 56
Study 11376256 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hour four dose of 225 mL dilute contrast material
Number of subjects: 56
Study 11376256 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hour six dose of 225 mL dilute contrast material
Number of subjects: 56
Study 11376256 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hour seven dose of 225 mL dilute contrast material
Number of subjects: 56
Study 8985215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 3
Study 8215474 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin + Cytarabine (IDA + Ara-C)
Number of subjects: 32
Study 8215474 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin + Cytarabine (DNR + Ara-C)
Number of subjects: 32
Study 3566389 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose cold high potassium cardioplegia (27 mEq of KCl/L)
Number of subjects: 56
Study 3566389 — intervention group
Group type: COMPARATOR
Intervention: Initial cold high potassium (27 mEq/L) cardioplegia followed by boluses of cold low potassium (7 mEq of KCl/L) solution
Number of subjects: 56
Study 28281936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposure (violent combat)
Number of subjects: 2510
Study 28281936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposure (proximity to wounding or death)
Number of subjects: 2510
Study 28281936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposure (explosive device exposure)
Number of subjects: 2510
Study 27327779 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention augmented by text messaging
Number of subjects: 30
Study 27327779 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23788510 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=24)
Number of subjects: 43
Study 23788510 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=19)
Number of subjects: 43
Study 22751086 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3-4.5 mg/d)
Number of subjects: 30
Study 22751086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19943060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (4 degrees C water for 2 min)
Number of subjects: 23
Study 19943060 — intervention group
Group type: COMPARATOR
Intervention: Isometric handgrip exercise (30% maximal voluntary contraction for 2 min)
Number of subjects: 23
Study 18662829 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone
Number of subjects: 693
Study 18662829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravitreal triamcinolone
Number of subjects: 693
Study 18662829 — intervention group
Group type: COMPARATOR
Intervention: focal/grid photocoagulation
Number of subjects: 693
Study 15945136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements usage
Number of subjects: 494
Study 15945136 — intervention group
Group type: COMPARATOR
Intervention: Non-metropolitan oldest-old
Number of subjects: 494
Study 15945136 — intervention group
Group type: COMPARATOR
Intervention: Metropolitan oldest-old
Number of subjects: 494
Study 15945136 — intervention group
Group type: COMPARATOR
Intervention: Metropolitan young-olds
Number of subjects: 494
Study 11844632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral tramadol (75 mg or 112.5 mg) plus acetaminophen (650 mg or 975 mg)
Number of subjects: 7
Study 11844632 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 7
Study 11844632 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination analgesics (tramadol plus acetaminophen)
Number of subjects: 7
Study 11844632 — intervention group
Group type: COMPARATOR
Intervention: Components alone (tramadol or acetaminophen)
Number of subjects: 7
Study 10338052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infiltrated into the harvest site
Number of subjects: 24
Study 10338052 — intervention group
Group type: COMPARATOR
Intervention: Control site (no bupivacaine)
Number of subjects: 24
Study 8522642 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for 6 days)
Number of subjects: 12
Study 8522642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily for 6 days)
Number of subjects: 12
Study 1781415 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (200 mg to 800 mg)
Number of subjects: 0
Study 6996930 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg clobazam (single daily dose)
Number of subjects: 45
Study 6996930 — intervention group
Group type: COMPARATOR
Intervention: 5 mg diazepam (3-times daily)
Number of subjects: 45
Study 31864126 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills education program
Number of subjects: 0
Study 31864126 — intervention group
Group type: COMPARATOR
Intervention: Placebo education program
Number of subjects: 0
Study 30944685 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw viscosity group (RV, n=58)
Number of subjects: 118
Study 30944685 — intervention group
Group type: COMPARATOR
Intervention: Low viscosity group (LV, n=60)
Number of subjects: 118
Study 30944685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study 28188268 — intervention group
Group type: EXPERIMENTAL
Intervention: GUIDED-HF strategy (tailored discharge plan, home visit, outpatient follow-up, coaching calls)
Number of subjects: 700
Study 28188268 — intervention group
Group type: COMPARATOR
Intervention: Standard ED discharge
Number of subjects: 700
Study 26235604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (43.2 Gy to the whole breast in 18 fractions for 24 days with a concomitant boost of 50.4 Gy to the tumor bed)
Number of subjects: 80
Study 26235604 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (45 Gy to the whole breast in 25 fractions for 44 days with a boost to the tumor bed of 59 Gy)
Number of subjects: 80
Study 23661337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 23661337 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 21587324 — intervention group
Group type: EXPERIMENTAL
Intervention: SICS with sutureless trabeculectomy (Group A)
Number of subjects: 30
Study 21587324 — intervention group
Group type: COMPARATOR
Intervention: SICS with trabeculectomy using W-shaped incision (Group B)
Number of subjects: 30
Study 19776297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention during rounds with nephrology unit team
Number of subjects: 600
Study 19776297 — intervention group
Group type: COMPARATOR
Intervention: Preintervention phase (control)
Number of subjects: 600
Study 17356445 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-bedding
Number of subjects: 0
Study 15835412 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle bevel facing upwards
Number of subjects: 48
Study 15835412 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel facing downwards
Number of subjects: 48
Study 11177119 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyltestosterone (MT) 40 mg/d for 3 days, then 240 mg/d for 3 days
Number of subjects: 17
Study 11177119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9394322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) at 4 mg/kg as a predialysis intravenous bolus followed by continuous infusion of 0.65 mg/kg/h
Number of subjects: 10
Study 9394322 — intervention group
Group type: COMPARATOR
Intervention: Dermatan sulphate (DS)
Number of subjects: 10
Study 8182901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) given orally or intravenously
Number of subjects: 6
Study 3358169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 30
Study 3358169 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study 28337949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 0
Study 28337949 — intervention group
Group type: COMPARATOR
Intervention: Masters‐Johnson sex therapy (MJST)
Number of subjects: 0
Study 28959461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 101
Study 28959461 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 101
Study 26194791 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) plus Treatment as Usual (TAU)
Number of subjects: 182
Study 26194791 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 182
Study 23895814 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent patients
Number of subjects: 25620
Study 23895814 — intervention group
Group type: COMPARATOR
Intervention: Nonpersistent patients
Number of subjects: 25620
Study 20356942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (Two-County Trial)
Number of subjects: 1000
Study 20356942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (UK Breast Screening Programme)
Number of subjects: 1000
Study 18437408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cineole
Number of subjects: 150
Study 18437408 — intervention group
Group type: COMPARATOR
Intervention: Control (combination of five different components)
Number of subjects: 150
Study 16767615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade)
Number of subjects: 50
Study 16767615 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 50
Study 16767615 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade sports drink
Number of subjects: 50
Study 16767615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted orange juice
Number of subjects: 50
Study 16767615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink and diluted orange juice
Number of subjects: 50
Study 14565783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (acetylsalicylic acid) therapy
Number of subjects: 15000
Study 14565783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15000
Study 10958177 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 15
Study 10958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PSL)
Number of subjects: 15
Study 10958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Glandular symptoms (G)
Number of subjects: 15
Study 10958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraglandular symptoms (EG)
Number of subjects: 15
Study 8840054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general and epidural anaesthesia with postoperative epidural analgesia (EPI)
Number of subjects: 99
Study 8840054 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia followed by postoperative intravenous analgesia (GA)
Number of subjects: 99
Study 1465583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CF)
Number of subjects: 310
Study 1465583 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin/Cefuroxime (T/C)
Number of subjects: 310
Study 6368777 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 91
Study 6368777 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin or Chloramphenicol
Number of subjects: 91
Study 31304862 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0
Study 31304862 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study 30439675 — intervention group
Group type: EXPERIMENTAL
Intervention: Positivity-approach training (4 sessions)
Number of subjects: 240
Study 30439675 — intervention group
Group type: COMPARATOR
Intervention: Sham training (4 sessions)
Number of subjects: 240
Study 27810633 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based education app
Number of subjects: 73
Study 27810633 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education (Control)
Number of subjects: 73
Study 25759568 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐BV (inertial sensor combined with BioVal software)
Number of subjects: 77
Study 22704860 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 128
Study 22704860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 21881326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac transplantation of unselected autologous bone marrow cells (BMC)
Number of subjects: 22
Study 21881326 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG concomitant with BMC-TX
Number of subjects: 22
Study 21881326 — intervention group
Group type: COMPARATOR
Intervention: Control group (CABG only)
Number of subjects: 22
Study 18782657 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCSF
Number of subjects: 59
Study 18782657 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 59
Study 17267529 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-Based Learning (CBL)
Number of subjects: 102
Study 17267529 — intervention group
Group type: COMPARATOR
Intervention: Human Patient Simulation (HPS)
Number of subjects: 102
Study 15111373 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 619
Study 15111373 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 619
Study 15111373 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/d
Number of subjects: 619
Study 15111373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 11434938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 64
Study 11434938 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 64
Study 11434938 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 64
Study 9766413 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest intensity of after care services
Number of subjects: 81
Study 9766413 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term home visiting services
Number of subjects: 81
Study 9766413 — intervention group
Group type: COMPARATOR
Intervention: After care services (various groups)
Number of subjects: 81
Study 9766413 — intervention group
Group type: COMPARATOR
Intervention: Early discharge with any after care system
Number of subjects: 81
Study 8153939 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1000 micrograms twice daily
Number of subjects: 17
Study 8153939 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg once daily
Number of subjects: 17
Study 3203661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise (leg extension exercise) at 50 times/min for 1 min with weights lifted through three different distances.
Number of subjects: 5